Table 1.
EoT-PET Characteristics, Central Review, Further Treatment, and Outcomes in Patients With Deauville Score 4 and 5 Positive Post-R-da-EPOCH PET/CT (n = 39; Listed by Increasing SUVmax in Post-R-da-EPOCH PET/CT)
| Patienta | Post-R-da-EPOCH EoT-PET/CT | Post- R-da-EPOCH Treatment |
Progression Status (mo Post EoT-PET/CT) | Vital Status (mo Post-R-da-EPOCH Initiation) | |||
|---|---|---|---|---|---|---|---|
| D5PSS (Local) | SUVmax | SUVmax/ SUVliver |
D5PSS at review | ||||
| D4-1 | 4 | 2.5 | 1.04 | 3 | No | CCR | ACR (68) |
| D4-2 | 4 | 2.9 | 1.44 | 4b | RT | CCR | ACR (83) |
| D4-3 | 4 | 3.0 | 1.36 | 3 | No | CCR | ACR (64) |
| D4-4 | 4 | 3.3 | 1.03 | 3 | No | Relapse (10) | ACR (43) |
| D4-5 | 4 | 3.4 | 1.42 | 4 | No | CCR | ACR (73) |
| D4-6 | 4 | 3.6 | 1.57 | 4 | No | CCR | ACR (64) |
| D4-7 | 4 | 3.8 | 1.15 | 3 | No | CCR | ACR (31) |
| D4-8 | 4 | 3.8 | 1.31 | 4 | No | CCR | ACR (31) |
| D4-9 | 4 | 3.9 | 1.22 | 3 | No | CCR | ACR (56) |
| D4-10 | 4 | 3.9 | 1.44 | 4 | No | CCR | ACR (56) |
| D4-11 | 4 | 3.9 | 1.39 | 4 | RT | CCR | ACR (56) |
| D4-12 | 4 | 4.0 | 1.08 | 3 | No | CCR | ACR (34) |
| D4-13 | 4 | 4.2 | 1.91 | 4 | No | CCR | ACR (38) |
| D4-14 | 4 | 4.3 | 1.34 | 3 | RT | CCR | ACR (71) |
| D4-15 | 4 | 4.5 | 1.80 | 4 | No | CCR | ACR (42) |
| D4-16 | 4 | 4.6 | 1.77 | 4 | No | CCR | ACR (76) |
| D4-17 | 4 | 4.6 | 2.30 | 4 | No | CCR | ACR (38) |
| D4-18 | 4 | 4.8 | 2.18 | 4 | RT | CCR | ACR (75) |
| D4-19 | 4 | 4.9 | 1.53 | 4 | No | CCR | ACR (28) |
| D4-20 | 4 | 5.5 | 1.72 | 4 | No | Relapse (8) | ACR (42) |
| D4-21 | 4 | 6.0 | 2.73 | 4b | RT | CCR | ACR (70) |
| D4-22 | 4 | 6.7 | 2.58 | 4 | No | Relapse (2) | ACR (16) |
| D5R-1 | 5 | 7.7 | 3.50 | NA | RT | CCR | ACR (34) |
| D5R-2 | 5 | 9.0 | 4.09 | NA | RT | CCR | ACR (31) |
| D5R-3 | 5 | 10.4 | >3 | NA | RT | CCR | ACR (49) |
| D5R-4 | 5 | 11.7 | >3 | NA | RT | CCR | ACR (32) |
| D5R-5 | 5 | 11.7 | >3 | NA | RT | CCR | ACR (28) |
| D5P-6 | 5 | 12.8 | >3 | NA | ST/ASCTi | Event at STI (5) | ACR (56) |
| D5R-7 | 5 | 15.0 | >3 | NA | ST/ASCTi | Event at STI (6) | DOD (18) |
| D5P-8 | 5 | 16.0 | >3 | NA | ST/ASCTi | Event at STI (5) | ACR (37) |
| D5P-9 | 5 | 16.2 | >3 | NA | ST/ASCTi | Event at STI (5) | ACR (100) |
| D5P-10 | 5 | 18.2 | >3 | NA | ST/ASCTi | Event at STI (6) | DOD (26) |
| D5P-11 | 5 | 21.8 | >3 | NA | ST/ASCTi | Event at STI (5) | DOD (16) |
| D5P-12 | 5 | 22.5 | >3 | NA | ST/ASCTi | Event at STI (7) | DOD (10) |
| D5P-13 | 5 | 22.7 | >3 | NA | ST/ASCTi | Event at STI (6) | DOD (25) |
| D5P -14 | 5 | 22.9 | >3 | NA | ST/ASCTi | Event at STI (6) | AWD (8) |
| D5P-15 | 5 | 27.7 | >3 | NA | ST/ASCTi | Event at STI (5) | ACR (78) |
| D5P-16 | 5 | NP | NP | NA | ST/ASCTi | Event at STI (5) | DOD (6) |
| D5P-17 | 5 | NP | NP | NA | ST/ASCTi | Event at STI (3) | DOD (15) |
D4 = D5PSS-4 per local interpretation; D5R = D5PSS-5 responsive by conventional restaging; D5P = D5PSS-5 with progressive or stable disease (SD/PD) by conventional restaging.
Unable to review according to D5PS.
ACR = alive in complete remission; AWD = alive with disease; CCR = continuous complete remission; DOD = died of disease; D5PSS = Deauville 5-point scale score; EOT = end-of-treatment; NA = not applicable; NP = not performed but considered as D5PSS-5 because of frankly progressive disease by conventional restaging; PD = progressive disease; PET/CT = positron emission tomography/computed tomography; RT = radiotherapy; ST/ASCTi = salvage therapy with the intention of autologous stem cell transplantation; STI = salvage therapy initiation; SUV = standardized uptake value.